Business Context and Reporting Period
This Form 8-K was filed by Aileron Therapeutics, Inc. (noting the input metadata referenced "Rein Therapeutics, Inc." incorrectly) on April 25, 2022. The company is a Delaware corporation with its principal executive offices in Boston, MA, and its common stock trades on the Nasdaq Capital Market under the symbol ALRN. The report addresses a material corporate governance event regarding executive leadership.
Key Financial Metrics
This filing is a current report regarding personnel changes and does not contain financial statements. Consequently, there is no data provided regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Executive Departure: Richard J. Wanstall, the Company's Chief Financial Officer (CFO), principal financial officer, and principal accounting officer, notified the Company of his resignation.
- Effective Date: The resignation is effective May 6, 2022.
- Reason for Departure: Mr. Wanstall is leaving to pursue another career opportunity. The filing explicitly states the resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Succession: The Company has initiated a search process to fill the position of Chief Financial Officer.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. The primary risk disclosed is the temporary absence of a CFO and the need to appoint a successor to manage financial operations and reporting.
Investor Verification Checklist
- Verify the timeline for the appointment of a new Chief Financial Officer.
- Confirm the interim arrangements for the principal financial and accounting officer roles between May 6, 2022, and the appointment of a successor.
- Review subsequent filings for any changes in financial reporting schedules or internal controls resulting from this leadership transition.